Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Spanish reimbursement system

- PMLiVE

MEDSCAPE’S NEW AGE OF CERTAINTY FOR CME

The CME industry is changing. More than ever, activities need to be prioritized and measured to increase their impact on patient outcomes. Improving patient outcomes is the core objective for...

Medscape Education Global

- PMLiVE

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...

Research Partnership

- PMLiVE

Novartis’ targeted combination therapy recommended by NICE to treat childhood brain tumours

Gliomas are the most common type of brain cancer in paediatric patients

- PMLiVE

Incyte announces agreement to acquire Escient Pharmaceuticals for $750m

The deal includes an MRGPRX2 antagonist with the potential to treat multiple mast cell-mediated diseases

- PMLiVE

AstraZeneca’s Voydeya granted EC approval to treat rare blood disease PNH

The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors

- PMLiVE

FDA approves ImmunityBio’s Anktiva for non-muscle invasive bladder cancer

NMIBC accounts for up to 80% of bladder cancer cases, the tenth most commonly diagnosed cancer globally

- PMLiVE

Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer’s treatment

AD is the most common form of dementia, which affects around 55 million people globally

- PMLiVE

Rare diseases – raising awareness, listening to patients, making a difference

PME speaks to Lorna Pender, Global Patient Engagement Lead at Clinigen, about the treatment options available to patients with rare diseases and the barriers that are hindering access

Black and white image of man and woman sitting at desk with laptop

Rebrand for Cheshire creative agency, LOVELIVE

Cheshire creative agency LOVELIVE has unveiled a new-look branding; coinciding with the launch of a new website as they celebrate 22% year on year growth and an exciting new focus.

LOVELIVE

- PMLiVE

Fox&Cat Relaunches With An Industry-First Efficiency & Effectiveness Planning Framework, ADAPTTM

F&C network team picture, March 2024 Fox&Cat relaunches today with its new people-first, senior consultant operating model and bespoke planning framework, ADAPTTM. The agency’s lean model...

Fox&Cat

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links